12:00 AM
Dec 23, 2013
 |  BC Week In Review  |  Company News  |  Deals

Orion, J&J deal

Orion granted Johnson & Johnson's Janssen Pharmaceuticals Inc. subsidiary exclusive, worldwide development rights and ex-European commercialization rights to Orion's adrenergic receptor alpha 2c ( ADRA2C) antagonists...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >